Extracellular Tau Levels Are Influenced by Variability in Tau That Is Associated with Tauopathies*

Celeste M. Karch, Amanda T. Jeng, and Alison M. Goate

From the Department of Psychiatry and Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, Missouri 63110

Background: Cerebrospinal fluid Tau levels are altered in tauopathies; however, the mechanism of Tau secretion is poorly understood.

Results: Tau isoforms and mutations alter extracellular Tau levels in cultured cells.

Conclusion: Tau is actively released, and Tau release is modified by variability in Tau that is associated with tauopathies.

Significance: Defining factors that influence Tau release is crucial to understanding Tau metabolism in tauopathies.

Tauopathies are a class of neurodegenerative diseases marked by intracellular aggregates of hyperphosphorylated Tau. These diseases may occur by sporadic mechanisms in which genetic variants represent risk factors for disease, as is the case in Alzheimer disease (AD). In AD, cerebrospinal fluid (CSF) levels of soluble Tau/pTau-181 are higher in cases compared with controls. A subset of frontotemporal dementia (FTD) cases occur by a familial mechanism in which MAPT, the gene that encodes Tau, mutations are dominantly inherited. In symptomatic FTD patients expressing a MAPT mutation, CSF Tau levels are slightly elevated but are significantly lower than in AD patients. We sought to model CSF Tau changes by measuring extracellular Tau in cultured cells. Full-length, monomeric extracellular total Tau and pTau-181 were detectable in human neuroblastoma cells expressing endogenous Tau, in human non-neuronal cells overexpressing wild-type Tau, and in mouse cortical neuropeutonic lines expressing MAPT mutations. Further, we demonstrated that the release of full-length, monomeric extracellular Tau is present in phosphorylated and dephosphorylated states. Furthermore, we demonstrated that the release of full-length, monomeric extracellular Tau is associated with Tauopathies, including Alzheimer disease (AD) and frontotemporal dementia (FTD), belong to a class of neurodegenerative diseases sharing the characteristic pathology of intracellular neurofibrillary tangles and extensive neuronal loss in the brain. Intracellular neurofibrillary tangles are composed of hyperphosphorylated Tau aggregates. Tau is an intracellular microtubule-associated protein, which functions to stabilize and facilitate the assembly of microtubules (1).

For more than a decade, extracellular Tau has been measured in human studies (reviewed in Ref. 2). Cerebrospinal fluid (CSF) levels of soluble total Tau and pTau-181 are associated with clinical AD (2) and are used as biomarkers for AD (3–9). CSF total Tau and pTau-181 levels are significantly elevated in clinically demented individuals compared with age-matched, cognitively normal controls (3–9). In symptomatic FTD patients expressing MAPT mutations, CSF Tau levels are slightly elevated but are significantly lower than in AD patients (5, 10). In stroke (11) and traumatic brain injury (12), CSF total Tau levels are briefly elevated after the initial insult, reflective of Tau release due to neuronal death; however, CSF phospho-Tau levels remain unchanged. CSF total Tau and pTau-181 levels can be used as a quantitative endophenotype to identify genes that influence Tau levels and contribute to AD pathogenesis (13, 14).

Tau protein in the CSF represents an intracellular protein in the extracellular space of the central nervous system. Recent studies suggest that extracellular Tau is detectable in cell and mouse models. Tau is detectable in the media of immortalized cell lines overexpressing wild-type Tau, and human/mouse Tau are detectable in the brain interstitial fluid and CSF of non-transgenic and Tau-P301S transgenic mice (18). In cultured cells, a robustly aggregating fragment of Tau containing the microtubule-binding region, is taken up by neighboring cells and induces intracellular wild-type (WT) Tau protein to aggregate (19). In mouse models, Tau aggregates can be propagated to distal regions of the brain (20, 21). Taken together, these data demonstrate that the Tau protein has prion-like properties and that once outside the cell, Tau proteins may induce toxicity and/or aggregation.

In this study, we sought to measure extracellular Tau in cultured neuronal cells and to characterize the mechanism by which WT Tau is released. In immortalized and primary neuronal cultures, we demonstrated that full-length, monomeric extracellular Tau is present in phosphorylated and dephosphorylated states. Furthermore, we demonstrated that the release of Tau is influenced by calcium and is likely mediated by the unconventional secretory pathway. We also provide evidence...
that Tau isoforms are released at different rates and that pathogenic mutations within Tau further alter Tau release. Together, we demonstrate that cells actively release Tau in the absence of disease or toxicity, and Tau release is modified by changes in the Tau protein that are associated with tauopathies.

**EXPERIMENTAL PROCEDURES**

**Site-directed Mutagenesis**—Human WT Tau cDNA (3R0N, 3R2N, 4R0N, or 4R2N) was expressed in the pcDNA3.1 vector (generously provided by Virginia Lee and Michael Goedert). Tau isoform nomenclature defines the length of the microtubule binding repeat (3R or 4R) and the presence or absence of exons 2 and 3 at the N terminus (ON or 2N). FTD-associated Tau mutations were introduced into the 3R2N or 4R2N Tau constructs by site-directed mutagenesis using the QuikChange II Site-directed Mutagenesis kit (Agilent). The sequence of each construct was verified by Sanger sequencing.

**Cell Lines and Transient Transfection**—Undifferentiated human neuroblastoma (SH-SY5Y) cells were cultured in Iscove's modified Dulbecco's medium supplemented with 10% fetal bovine serum (FBS), 1% l-glutamine, and penicillin/streptomycin. Human embryonic kidney (HEK293T) cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% l-glutamine, and penicillin/streptomycin. For transient transfection, HEK293T cells were cultured in 6-well lysis-coated plates. Upon reaching 90% confluence, cells were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol and harvested after 24 h.

**Primary Mixed Neuronal Cultures**—Glial cultures, to serve as a feeder layer, were isolated from 2-day-old postnatal Swiss Webster mouse pups following standard protocols (22). Neuronal cultures were isolated from mice at embryonic day 18 as previously described (22). Neocortices were extracted and plated on glial cultures and grown at 37 °C for 14 days.

**Tau ELISA**—Media was collected and centrifuged at 3000 × g for 10 min at 4 °C to remove cell debris. Cell lysates were extracted in lysis buffer (50 mM Tris, pH 7.6, 1 mM EDTA, 150 mM NaCl, 1% Triton X-100, phosphatase and protease inhibitors) and incubated on ice for 5 min. Lysates were then centrifuged at 14,000 × g for 10 min at 4 °C, and the resulting supernatant was saved for analysis. Media and cell lysates were analyzed for total Tau and phospho-Tau using commercially available ELISA kits (Invitrogen) specific to human total Tau, mouse total Tau, and p-Tau-181. To account for protein concentration, total protein in cell lysates was measured by BCA assay according to manufacturer's protocol. ELISA values were obtained (pg/ml) and corrected for total intracellular protein (μg/ml), producing a final unit of pg/μg.

**Immunoprecipitation**—Media and cell lysates were precleared with Protein G beads (Thermo Scientific). Pre-cleared supernatants were incubated overnight at 4 °C with the antibodies indicated. Supernatant-antibody complexes were then incubated with Protein G beads at room temperature for 2 h. After washing, proteins were dissociated from the Protein G beads by incubating the beads in Laemmli sample buffer (23) supplemented with 5% β-mercaptoethanol at 95 °C for 10 min.

**Pulse-Chase**—To measure the half-life of intracellular Tau protein and the release rate of Tau protein in SH-SY5Y cells, cells were plated in 60-mm lysis-coated dishes (Biocoat) and grown at 37 °C overnight. Cells were conditioned in methionine-free media (Invitrogen) for 1 h and pulsed with 300 μCi of [35S]methionine (PerkinElmer Life Sciences) in methionine-free media for 1 h. Cells were then washed and chased with complete media for 1, 3, 6, 12, 18, and 24 h. Culture media and cell lysates were extracted and immunoprecipitated as described above. Immunoblots were exposed to autoradiography film and developed to visualize Tau protein bands.

**Inhibition of Protein Secretion**—Cells were treated with the following chemicals to inhibit protein trafficking: 2 μg/ml of brefeldin A (BFA, Sigma), 2 μM BAPTA-AM (Sigma), 0.5 mM EDTA (Fisher), 100 mM thapsigargin (Sigma), 100 mM ionomycin (Sigma), 2 μM chloroquine (CQ, Sigma), 2 mM methylamine (Fisher), 1 μM paclitaxel (Sigma), 25 μM pseudolitic acid B (PAB, Enzo Life Science). All reagents were diluted in DMSO. After growing SH-SY5Y cells overnight at 37 °C, culture media was removed and replaced with media containing the compounds listed above, diluted 1:1000, for 6 h. Culture media and cells were subsequently collected and prepared for ELISA analysis (as described above). Results were expressed relative to DMSO-treated controls.

**Lactate Dehydrogenase (LDH) Assay**—Cytotoxicity was measured in SH-SY5Y cells using an LDH assay kit (Clontech). Cells were incubated with untreated LDH assay media (low control) or with LDH assay media supplemented with 1% Triton X-100 (high control), DMSO (1:1000), or protein trafficking compounds for 6 h. Cytotoxicity was also measured in HEK293T cells transiently transfected with vectors expressing GFP, WT, or mutant Tau for 24 h. Media from these cells was then incubated with a reaction mixture containing tetrazolium salt and measured at 490 nm. Cytotoxicity was expressed relative to the percentage of maximal cell lysis.

**Exosome Preparation**—SH-SY5Y cells (10 10-cm plates) were incubated for 48 h in exosome-free media. Exosomes were then isolated as previously described (24).

**Biotinylation**—Tau at the cell surface was measured by biotinylation of cultured cells with NHS-SS biotin (Thermo Scientific). Untransfected SH-SY5Y cells were treated with biotin (1 mg/ml) for 30 min, washed, and collected.

To measure Tau internalization, cells were biotinylated (1 mg/ml) for 30 min on ice, which inhibits endocytosis. The internalized protein fraction was measured by incubating biotinylated cells at 37 °C for 10 min. Cells were subsequently treated with biotin stripping buffer (50 mM 2-mercaptoethanesulfonic acid, 100 mM NaCl, and 2.5 mM CaCl2 in 50 mM Tris-HCl, pH 7.6) to digest biotinylated proteins at the cell surface.

Cell lysates were extracted as described above and incubated with strepavidin beads (Thermo Scientific). Protein-antibody complexes were dissociated by incubation in Laemmli sample buffer (23).

**Immunoblotting**—Standard SDS-PAGE was performed in 4–20% Criterion Tris-HCl gels (Bio-Rad). Samples were boiled in Laemmli sample buffer (23) prior to electrophoresis. Immunoblots were probed with the antibodies listed below.
**RESULTS**

Increasing evidence in human subjects and cell/mouse models suggests that Tau is detectable outside the cell (2, 15–17, 25). We sought to measure extracellular Tau in cells that endogenously express Tau, to determine the mechanism by which Tau is released, and to determine how genetic variants associated with tauopathies influence extracellular Tau levels.

**Extracellular Tau Is Full-length and Monomeric**—We have previously demonstrated that extracellular total and phosphorylated Tau (pTau-181 and pTau-396) are detectable in the media in human neuroblastoma SH-SY5Y cells endogenously expressing human Tau (17). To determine whether mouse cortical cells also release Tau into the media, cortical neurons were isolated from the brains of mouse embryos (E18) and grown on an astrocyte monolayer. At DIV14, media and cell lysates were collected and analyzed by ELISA. Total Tau was detectable in both the media and cell lysates of mouse cortical cultures (Fig. 1A). In accordance with observations that we made in human neuroblastoma cells (17), extracellular Tau represents a small fraction of the total Tau detected (Fig. 1A). We were unable to detect extracellular pTau-181 in the media by ELISA (data not shown). However, by immunoprecipitation, we demonstrate that total Tau and pTau-181 are detectable in the media of mouse cortical cultures (Fig. 1B).

A subset of intracellular Tau is truncated in cultured cells (26) and in tangles from autopsy-confirmed AD brain tissue (27, 28). We have previously demonstrated that extracellular Tau is predominantly full-length in immortalized cell lines expressing human 4R2N WT and P301S Tau (as described above). Media was aspirated after 24 h and replaced with media supplemented with 100 µM cycloheximide. Media and cells were collected at the designated time points after cycloheximide treatment.

**Tau Uptake by HEK293T Cells**—HEK293T cells were transiently transfected with wild-type (4R2N) Tau in the pcDNA3.1 vector or empty vector (as described above). Media was replaced 24 h after transfection. After an additional 24 h in culture, media was removed and placed on untransfected HEK293T cells, which do not express Tau. Cells were collected 24 and 48 h after treatment. Media and cell lysates were collected and analyzed by ELISA, immunoblotting, and immunocytochemistry.
Extracellular Tau Is Influenced by Variability in Tau

Tau monomers, oligomers, or fibrils could explain the propagation of Tau aggregates. To determine which forms of Tau are present outside the cell, cell lysates and media from SH-SY5Y cells were passed through a 50-kDa size exclusion column, which captures proteins that are 70 kDa and smaller in size. In this cell system, intracellular Tau was predominantly 70 kDa and smaller (Fig. 2A). To a lesser extent, we were able to detect intracellular Tau in the fraction representing proteins greater than 70 kDa (Fig. 2A). Thus, our assay is capable of detecting species of Tau that are larger than a monomer. In the media, we could only detect extracellular Tau proteins at or below 70 kDa (Fig. 2B). The absence of extracellular Tau in the >70 kDa fraction does not eliminate the possibility that multimeric Tau exists outside the cell. This ELISA may not be sufficiently sensitive to detect multimeric forms of Tau if they represent a small fraction of the total extracellular Tau. Together, these findings demonstrate that extracellular Tau detected in this assay is predominantly monomeric.

It has been proposed that Tau present in the CSF of AD patients represents Tau released from dying neuronal cells in the brain. To determine the extent to which cell death contributes to changes in extracellular Tau levels in our cell model, we treated SH-SY5Y cells with increasing concentrations of H2O2. Cytotoxicity and intracellular/extracellular Tau levels were then measured. Treatment of cells with 1 mM H2O2 produced significant cytotoxicity compared with untreated controls (Fig. 3A). Cytotoxicity was increased with increasing H2O2 concentrations, achieving 100% toxicity, relative to maximal cell lysis by 1% Triton X-100, with treatment of 100 mM H2O2 (Fig. 3A). Extracellular Tau levels, however, were only significantly elevated in cells achieving at least 40% cell death: 10 and 100 mM H2O2 (Fig. 3B). Extracellular Tau changes that were induced by cytotoxicity were 5–80-fold above controls (Fig. 3B). Thus, low levels of cytotoxicity are not sufficient to increase extracellular Tau levels in our cell model.

Isoform-specific Release of Extracellular Tau—To determine the rate at which endogenous human Tau is released from the cell, we radiolabeled SH-SY5Y cells. In cell lysates, three species of Tau are prominent (Fig. 4A). The most abundant Tau species is very stable (Fig. 4A, white arrow). The other two Tau species are much less abundant and are turned over more rapidly (Fig. 4A, black and gray arrows). In the media, Tau is detectable 6 h after chase (Fig. 4A). Interestingly, the most abundant Tau isoform outside the cell corresponds to a band of lesser abundance in the cell lysates (Fig. 4A, black arrow). Thus, neuroblastoma cells release Tau species at different rates, independent of their abundance in the cell. These findings are in agreement with a recent report in which Tau is measured in mouse brain tissue and interstitial fluid (18). We are unable to define the species of Tau that are most abundant inside and outside these cells. These species may represent phosphorylated and dephosphorylated forms of Tau or Tau isoforms produced by alternative splicing. The specific release of a subset of Tau species in these cells points to an active mechanism of Tau transport out of the cell.

SH-SY5Y cells express Tau isoforms that differ in the N-terminal insert and microtubule binding repeat length. SH-SY5Y cells endogenously express the 2N and 0N isoforms of Tau at relative equal levels, and both are more highly expressed than the 1N isoforms of Tau (29). To determine whether the differences in Tau species that we observed inside and outside the cell (Fig. 4A) reflect isoform-specific differences in Tau release, we cloned wild-type (WT) Tau cDNA differing at the N terminus and in the microtubule repeat length (3R0N, 3R2N, 4R0N, 4R2N) into the pcDNA3.1 vector and transiently expressed each construct in HEK293T cells. After 24 h in culture, cells expressing Tau 3R2N exhibited the highest ratio of extracellular/intracellular Tau (Fig. 4B), whereas Tau 4R2N exhibited the lowest ratio of extracellular/intracellular Tau (Fig. 4B). Cells expressing Tau isoforms that do not contain N-terminal exons 2 and 3 (3R0N and 4R0N) have a similar ratio of extracellular/intracellular Tau (Fig. 4B), which is significantly lower than 3R2N and significantly higher than 4R2N. Intracellular Tau protein levels (Fig. 4C) and mRNA levels (Fig. 4D) do not differ between these Tau isoforms, illustrating that differences in extracellular/intracellular Tau ratios are driven by changes in extracellular Tau. Furthermore, Tau isoforms do not induce cytotoxicity (Fig. 4E). Our findings that Tau isoforms influence extracellular Tau levels provides further evidence that Tau release is an active and specific process.

Extracellular Tau Is Released via the Unconventional Secretory Pathway—To determine the mechanism by which neuroblastoma cells release Tau, SH-SY5Y cells, expressing endogenous human Tau, were treated with compounds that inhibit components of the classical and unconventional secretory pathways. Total Tau was then measured in cell lysates and media by ELISA. Cytotoxicity, as assessed by LDH assay, was not observed in any treatment conditions (Fig. 5B). Heat shock
SH-SY5Y cells at 40 °C produced a significant increase in extracellular Tau levels compared with cells incubated at 37 °C (Fig. 5A). Passive transport of proteins is unaffected by temperature change (30). Thus, Tau is not transported out of the cell by passive diffusion. Instead, fitting with our previous observations (Fig. 4), it is likely that Tau is actively transported out of the cell.

To determine whether Tau is released via the classical secretory pathway, in which proteins are transported from the endoplasmic reticulum to the Golgi apparatus to secretory vesicles,
SH-SY5Y cells were treated with 2 μg/ml of BFA for 6 h. BFA causes disassembly of the Golgi complex (Fig. 5, C and D) (31), resulting in inhibition of retrograde and anterograde transport. Total Tau was unchanged in the intracellular and extracellular fractions in the BFA-treated cells compared with DMSO-treated controls (Fig. 5A). Aβ40 levels decrease, as expected, with BFA treatment (Fig. 5E) (32). Thus, it is unlikely that Tau is released primarily via the classical secretory pathway.

Calcium signaling is important in early endosome fusion, exocytosis, and exosome-mediated release (33–35). Thus, we sought to determine the effects of altering calcium levels on extracellular Tau. Treatment of cells with a calcium chelator, 0.5 mM EDTA, did not produce changes in intracellular or extracellular total Tau compared with DMSO-treated controls (Fig. 5A). EDTA, however, is not membrane permeable. Treatment of cells with BAPTA-AM, a membrane permeable calcium chelator, resulted in a significant increase in extracellular total Tau without altering intracellular total Tau levels (Fig. 5A). Conversely, increasing intracellular calcium levels by treatment with 50 nM thapsigargin, which causes cytosolic Ca\(^{2+}\) release from Ca\(^{2+}\) stores in the ER (36), or 10 nM ionomycin, a calcium ionophore, produced significantly elevated extracellular Tau levels without changing intracellular Tau levels (Fig. 5A). Thus, whereas calcium is not required for Tau release, calcium homeostasis is a critical mediator of Tau release.

Calcium signaling is important in the endocytic pathway (33). We examined the effect of inhibition of the endocytic pathway on extracellular Tau. Treatment of cells with 2 mM methylamine, which prevents endosome and lysosome acidification (37, 38), resulted in a slight increase in extracellular Tau (Fig. 5A); however, this increase was not significantly different from DMSO controls. Treatment of cells with 25 μM CQ, which perturbs endosome acidification (34, 39), produced a significant increase in extracellular Tau without changing intracellular Tau (Fig. 5A). CQ also perturbs calcium signaling in the cell (40), providing further evidence that calcium homeostasis influences Tau release.

Aggregation-prone proteins such as prion protein, α-synuclein, and β-amyloid are packaged in multivesicular bodies and released by the cell in exosomes (41–43). To determine whether Tau is also packaged and released in exosomes, SH-SY5Y cells were cultured in exosome-free media for 48 h. Exosomes were purified from the media by a series of high-speed centrifugation steps. Immunoblots were probed with antibodies specific to the C terminus of Tau or Alix, an exosomal marker. F, supernatant; G, exosome pellet. Immunoblots are representative of 2 replicate experiments. Graphs represent average ± S.E. PAB, pseudoloric acid B, * p < 0.01; #, p < 0.05.

FIGURE 5. Tau is actively released in human neuroblastoma cells. A, SH-SY5Y cells, expressing endogenous Tau, were treated with compounds that inhibit protein secretory pathways and extracellular (white bar), intracellular (black bar), and total (striped bar) Tau were measured by total Tau ELISA. Values are expressed relative to total intracellular protein, as measured by a BCA assay. Values adjusted for total intracellular protein were then normalized to DMSO controls. Data shown are representative of 6 replicate experiments. B, compounds that do not induce cytotoxicity. LDH assay measured as percent maximal lysis. SH-SY5Y cells, expressing endogenous Tau, were treated with compounds that inhibit protein secretory pathways for 6 h at 37 °C. Data are representative of at least 3 replicates. C–E, cellular response to compounds affecting protein transport. SH-SY5Y cells were fixed in 4% paraformaldehyde. Cells were visualized at ×40 magnification. Cells were stained with an antibody specific to the Golgi apparatus (giantin) and secondary antibody anti-Alexa Fluor 594. C, SH-SY5Y cells were treated with a control compound (DMSO) for 6 h. D, cells were treated with a compound that causes disassembly of the Golgi apparatus (BFA) for 6 h. E, extracellular Aβ40 levels are reduced in the presence of BFA. Media from SH-SY5Y cells treated with BFA for 6 h were analyzed by ELISA (Invitrogen) for Aβ40 levels. Values are expressed relative to total intracellular protein, as measured by a BCA assay. Data shown are representative of 3 replicate experiments. F and G, Tau is not packaged and released in exosomes. SH-SY5Y cells were cultured in exosome-free media for 48 h. Exosomes were purified from the media by a series of high-speed centrifugation steps. Immunoblots were probed with antibodies specific to the C terminus of Tau or Alix, an exosomal marker. F, supernatant; G, exosome pellet. Immunoblots are representative of 2 replicate experiments. Graphs represent average ± S.E. PAB, pseudoloric acid B, *, p < 0.01; #, p < 0.05.

Extracellular Tau Is Influenced by Variability in Tau
failed to capture biotinylated Tau protein in the culture media 6 h after cells were biotinylated (Fig. 6C). This does not eliminate the possibility that cell surface Tau is released into the media. Because we are attempting to capture a subset of extracellular Tau, which was biotinylated at the cell surface, our methods of measurement may not be sufficiently sensitive. Alternatively, biotinylated extracellular Tau may be processed quickly or proteolyzed in such a way that limits detection. The presence of Tau at the cell surface suggests that Tau may be released via protein conducting channels in the plasma membrane.

Tau functions to stabilize microtubules. The stabilization or destabilization of microtubules with paclitaxel or PAB, respectively (Fig. 7, A–C), produced significant changes in intracellular and extracellular total Tau levels (Fig. 7D). This indicates that perturbation of Tau function in the cell can lead to altered homeostasis of Tau inside and outside the cell; however, the ability of Tau to bind to microtubules is not required for Tau retention or release.

**FTD-associated Tau Mutations Alter Extracellular Tau Levels**—FTD-associated Tau mutations are associated with Tau tangles in the brain. To determine whether FTD-associated Tau mutations alter intracellular or extracellular Tau levels, we overexpressed vectors containing 4R2N Tau WT, P301L, and R406W in HEK293T cells and measured intracellular and extracellular Tau. Extracellular Tau was significantly lower in cells expressing FTD-associated Tau mutations (P301L and R406W) compared with Tau WT-expressing cells (Fig. 8, A and B). Intracellular Tau levels did not differ between mutant and WT expressing cells (Fig. 8C). Similarly, an FTD-associated Tau mutation (R406W) in the 3R2N Tau isoform produced significantly less extracellular Tau compared with 3R2N WT (Fig. 8, D and E) without altering intracellular Tau levels (Fig. 8F). LDH assays demonstrate that the observed differences are not due to cytotoxic effects of the Tau constructs (Fig. 4E). Thus, FTD-associated Tau mutations in 4R and 3R Tau isoforms influence extracellular Tau levels in cultured cells.

Because we observed differences in the rate at which certain Tau species are released from the cell (Fig. 4A), we tested whether the observed differences in extracellular Tau levels in WT and mutant-expressing cells are due to the rate of Tau release. Cells expressing 4R2N Tau P301S produced a significant decrease in extracellular Tau levels similar to cells expressing 4R2N Tau P301L and R406W (Fig. 8G). To determine how an FTD-associated Tau mutation influences Tau release rates, cells expressing WT and P301S Tau cells were treated with cycloheximide, which inhibits protein synthesis, and total Tau was measured in the media by ELISA. WT and P301S Tau were released at a similar level for the first 6 h post-cycloheximide treatment; however, after 6 h, WT extracellular Tau levels con-
Cells Propagate Full-length Wild-type Tau—Cells can internalize extracellular aggregates of the microtubule-binding region of Tau (19, 48). To determine whether cells can take up extracellular full-length Tau in this cell system, we treated naive HEK293T cells, which do not express endogenous Tau, with conditioned media from cells overexpressing Tau. Within 24 h of treatment with conditioned media, Tau and microtubules co-localize, indicating that once taken up by the cell, Tau retains its normal function (Fig. 9, A–C). This observed decrease likely represents Tau that is taken up by the cell. This reduction may also represent some turnover of the Tau protein; however, we demonstrate that Tau is very poorly characterized. Calcium signaling plays many important roles in the cell. Our findings that alteration of intracellular calcium levels in either direction increases extracellular Tau metabolism, a fraction of Tau is released by the cell.

DISCUSSION

The presence of Tau in human CSF from healthy and diseased individuals suggests that Tau is released by the cell under normal and pathologic conditions (2). In this study, we sought to characterize the mechanism by which endogenous and mutant Tau is released in cultured cells. Full-length, monomeric extracellular Tau is present in immortalized cell lines and primary neuronal cultures. Endogenous Tau release is influenced by calcium via the unconventional secretory pathway. Furthermore, Tau isoforms and FTD-associated Tau mutations influence the rate of Tau release. Thus, cells actively release endogenous Tau in the absence of toxicity, and Tau release is modified by genetic changes in Tau that are associated with tauopathies.

Previous studies in immortalized cell lines overexpressing Tau have demonstrated that a fraction of total Tau is present outside the cell (15–17). In this study, we demonstrate that extracellular Tau (total and phospho-Tau) is present in the media of neuroblastoma cells (SH-SY5Y) and in primary mouse cortical cultures in the absence of overexpression. We have further demonstrated that endogenous Tau is actively released by the cell. We provide two independent lines of evidence for this conclusion: 1) in pulse-chase experiments, specific Tau species are more rapidly released than other Tau species and 2) heat shocked cells produce more extracellular Tau than cells cultured at 37 °C. Thus, our cell culture studies, together with observations in human CSF studies in healthy individuals, provides evidence for the hypothesis that during normal Tau metabolism, a fraction of Tau is released by the cell.

The mechanism by which Tau is actively released from the cell is complex. We demonstrate that endogenous human Tau is actively released via the unconventional secretory pathway, as Tau levels are not influenced by Golgi apparatus disassembly. The unconventional secretory pathway involves vesicular and non-vesicular pathways that are independent of the ER/Golgi-mediated secretory pathway (49); however, these pathways are poorly characterized. Calcium signaling plays many important roles in the cell. Our findings that alteration of intracellular calcium levels in either direction increases extracellular Tau levels suggests that calcium homeostasis is critical for controlling intracellular and extracellular Tau levels.

Several reports suggest that extracellular recombinant Tau induces an increase in intracellular calcium levels by binding to and activating muscarinic receptors (50, 51). Exogenous α-sy-
nuclein, β-amyloid, and prion protein also induce calcium dysregulation in cultured neurons (52, 53). Dysregulation of intracellular calcium signaling may play a role in AD pathogenesis (54–56). Based on our findings, we hypothesize that dysregulation of intracellular calcium levels in the neurons of AD brains could contribute to higher levels of extracellular Tau, which are reflected in increased CSF Tau levels in AD patients.

Aggregation prone proteins that are associated with neurodegenerative diseases have been reported to be released from the cell in exosomes (41–43, 57, 58). Despite recent reports (59, 60), we failed to detect extracellular Tau in exosomes from neuroblastoma cells expressing endogenous human Tau. Similarly, Tau is not detectable in exosomes purified from primary mouse neuronal cultures (61, 62). Extracellular Tau is reported to co-localize with exosomes; however, Tau only appears to co-localize with exosomes when Tau expression levels are high (59, 60). The cell may package Tau in exosomes to compensate for protein overexpression; however, this is not relevant to normal Tau metabolism or disease. Alternatively, Tau may stick to the outside of exosomes. If extracellular Tau were primarily packaged into exosomes, we would not detect the protein in the non-denaturing conditions used in this study. Additionally, Yamada and colleagues (18) demonstrate that human and mouse Tau are detectable in the interstitial fluid and CSF using a 100-kDa microdialysis probe, which is not large enough to capture exosomes. Thus, the majority of extracellular Tau is not packaged in vesicular structures when transported out of the cell.

All 4 isoforms of Tau expressed in HEK293T cells (3R0N, 3R2N, 4R0N, and 4R2N) were detected outside of the cell. We propose that all Tau isoforms are released by a similar mechanism. We hypothesize that the differences we observe between the 4 isoforms are due to the way that each protein folds, which may facilitate or hinder transport across the plasma membrane.

We hypothesize that the cell actively releases Tau and that genetic factors enriched in patients with tauopathies alter the release of Tau from cells in the brain. CSF total/pTau-181 levels are significantly elevated in AD patients compared with age-matched, cognitively normal controls (4, 8). In symptomatic FTD patients carrying the P301L MAPT mutation, CSF total Tau levels are elevated relative to controls but lower than symptomatic AD patients (10); however, little is known of how CSF Tau changes over the course of this tauopathy. We demonstrate that extracellular Tau levels are significantly lower in cells expressing FTD-associated Tau mutations compared with WT-expressing cells. This difference may reflect a slower rate of Tau release from the cell. If this is the case, retention of mutant Tau by the cell has implications for aggregation and downstream toxic effects. Alternatively, the Tau released by mutant-expressing cells may adopt protein conformations that cannot be captured by this assay. Yamada and colleagues (18) have demonstrated that interstitial fluid Tau levels drop in symptomatic Tau-P301S transgenic mice (12 months) compared with young Tau-P301S mice, which correlates with the accumulation of formic acid soluble Tau in the hippocampus. Together, we provide evidence for a shared phenotype in cells expressing FTD-associated Tau mutations that are located in 2
different exons (P301L and R406W) and which have differing effects on microtubule assembly (63).

Tau splicing has also been implicated as a risk factor for tauopathies. Several FTD-associated Tau mutations produce altered Tau splicing, resulting in higher expression levels of Tau with exon 10 (4R) in the brain. Additionally, two extended haplotypes, spanning 1.8 Mb, occur in the MAPT region. The H1 Tau haplotype is associated with increased risk for several sporadic tauopathies: progressive supranuclear palsy (64), corticobasal degeneration (65), Alzheimer disease (66), and Parkinson disease (67). In AD brains, the H1 Tau haplotype is associated with an increase in the ratio of 4R to 3R Tau mRNA (68). SH-SY5Y cells, which express endogenous human Tau, are homozygous for the Tau H1 haplotype (data not shown). Our studies indicate that Tau isoforms are released at differing rates, whereby both the N terminus and microtubule binding repeat length contribute to release rate: 4R Tau isoforms (4R2N and 4R0N) are much less abundant outside the cell compared with 3R Tau isoforms (3R2N and 3R0N). Our observations that 4R Tau isoforms are less abundant outside the cell than 3R Tau isoforms suggests that the differential splicing of the Tau protein observed in FTD may also influence the retention of certain Tau isoforms within the cell. Together, we demonstrate that Tau is an intracellular and extracellular protein. The relative ratio of intracellular and extracellular Tau may be important for normal cell function, as FTD and Tau isoforms associated with tauopathies alter these ratios.

Acknowledgments—We thank Joy Snider and the Hope Center Viral Vector Core at Washington University in assistance of the primary mouse cortical cells. We thank Virginia Lee for providing 3R0N and 4R2N Tau constructs and Michel Goedert for providing 3R2N and 4R0N Tau constructs.

REFERENCES

1. Cleveland, D. W., Hwo, S. Y., and Kirschner, M. W. (1977) Purification of Tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. J. Mol. Biol. 116, 207–225
2. Craig-Schapiro, R., Fagan, A. M., and Holtzman, D. M. (2009) Biomarkers of Alzheimer disease. Neurobiol. Dis. 35, 128–140
3. Csernansky, J. G., Miller, J. P., McKeel, D., and Morris, J. C. (2002) Relationships among cerebrospinal fluid biomarkers in dementia of the Alzheimer type. Alzheimer Dis. Assoc. Disord. 16, 144–149
4. Galasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Khodolenko, D., Schenk, D., Lieberburg, I., Miller, B., Green, R., Bashard, R., Kertiles, L., Boss, M. A., and Seubert, P. (1998) High cerebrospinal fluid tau and low amyloid β levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch. Neurol. 55, 937–945
5. Green, A. J., Harvey, R. I., Thompson, E. J., and Rossor, M. N. (1999) Increased Tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer disease. Neurosci. Lett. 259, 133–135
6. Jensen, M., Basun, H., and Lannfelt, L. (1995) Increased cerebrospinal fluid Tau in patients with Alzheimer disease. Neurosci. Lett. 186, 189–191
7. Tato, R. E., Frank, A., and Hernanz, A. (1995) Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. J. Neurol. Neurosurg. Psychiatry. 58, 280–283
8. Vigo-Pelfrey, C., Seubert, P., Barbour, R., Blomquist, C., Lee, M., Lee, D., Coria, F., Chang, L., Miller, B., and Lieberburg, I. (1995) Elevation of microtubule-associated protein Tau in the cerebrospinal fluid of patients with Alzheimer disease. Neurology 45, 788–793
9. Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., and Holtzman, D. M. (2007) Cerebrospinal fluid Tau/β-amyloid ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 64, 343–349
10. Hampel, H., and Teipel, S. J. (2004) Total and phosphorylated Tau protein. Evaluation as core biomarker candidates in frontotemporal dementia. Dement. Geriatr. Cogn. Disord. 17, 350–354
11. Hesse, C., Rosengren, L., Andreasson, N., Davidson, P., Vanderstichele, H., Vanmechelen, E., and Blennow, K. (2001) Transient increase in total Tau but not phospho–tau in human cerebrospinal fluid after acute stroke. Neurobiol. Lett. 297, 187–190
12. Ost, M., Nylén, K., Csaibik, L., Ohrfelt, A. O., Tullberg, M., Wikkelso, C., Neillgärd, P., Rosengren, L., Blennow, K., and Nellgärd, B. (2006) Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology 67, 1600–1604
13. Kauwe, J. S., Cruchaga, C., Mayo, K., Fenoglio, C., Bertelsen, S., Nowotny, P., Galimberti, D., Scarpini, E., Morris, J. C., Fagan, A. M., Holtzman, D. M., and Goate, A. M. (2008) Variation in MAPT is associated with cerebrospinal fluid Tau levels in the presence of amyloid-β deposition. Proc. Natl. Acad. Sci. U.S.A. 105, 8050–8054
14. Cruchaga, C., Kauwe, J. S. K., Mayo, K., Spiegel, N., Bertelsen, S., Nowotny, P., Shah, A. R., Abraham, R., Hollingsworth, P., Harold, D., Owen, M. M., Williams, J., Lovestone, S., Peskind, E. R., Li, G., Leverenz, J. B., Galasko, D., Initiative, A. s. D. N., Morris, J. C., Fagan, A. M., Holtzman, D. M., and Goate, A. M. (2010) SNPs associated with cerebrospinal fluid phospho-Tau levels influence rate of decline in Alzheimer disease. PLoS Genet. 6, e10309
15. Kim, W., Lee, S., and Hall, G. F. (2010) Secretion of human Tau fragments resembling CSF-Tau in Alzheimer disease is modulated by the presence of the exon 2 insert. FEBS Lett. 584, 3085–3088
16. Kim, W., Lee, S., Jung, C., Ahmed, A., Lee, G., and Hall, G. F. (2010) Interneuronal transfer of human Tau between Lamprey central neurons in situ. J. Alzheimers Dis. 19, 647–664
17. Karch, C. M., Jeng, A. T., and Goate, A. M. (2012) Calcium phosphatase calcineurin influences Tau metabolism. Neurobiol. Aging. in press
18. Yamada, K., Cirrito, J. R., Stewart, F. R., Jiang, H., Finn, M. B., Holmes, B. B., Binder, L. I., Mandelkow, E. M., Diamond, M. I., Lee, Y. M., and Holtzman, D. M. (2011) In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid Tau levels in P301S human Tau transgenic mice. J. Neurosci. 31, 13110–13117
19. Frost, B., Jacks, R. L., and Diamond, M. I. (2009) Propagation of Tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 284, 12845–12852
20. Clavaguera, F., Bolmont, T., Crowther, R. A., Abramowski, D., Frank, S., Probst, A., Fraser, G., Stalder, A. K., Beibel, M., Staufenbiel, M., Jucker, M., Goedert, M., and Tolnay, M. (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 11, 909–913
21. Liu, L., Drouet, V., Wu, J. W., Witter, M. P., Small, S. A., Clelland, C., and Duff, K. (2012) Trans-synaptic spread of Tau pathology in vivo. PLoS One 7, e31302
22. Choi, D. W. (1987) Ionic dependence of glutamate neurotoxicity. J. Neurosci. 7, 369–379
23. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680–685
24. Théry, C., Amigorena, S., Raposo, G., and Clayton, A. (2006) Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr. Protoc. Cell Biol. Suppl. 30, 3.21.1–3.22.29
25. Ono, T., Yamamoto, H., Tashima, K., Nakashima, H., Okumura, E., Yamada, K., Hisanaga, S., Kishimoto, T., Miyakawa, T., and Miyamoto, E. (1995) Dephosphorylation of abnormal sites of Tau factor by protein phosphatases and its implication for Alzheimer disease. Neurochem. Int. 26, 205–215
26. Wang, Y. P., Binart, J., Pickhardt, M., Mandelkow, E., and Mandelkow, E. M. (2007) Stepwise proteolysis liberates Tau fragments that nucleate the Alzheimer-like aggregation of full-length Tau in a neuronal cell model. Proc. Natl. Acad. Sci. U.S.A. 104, 10252–10257
27. Gamblin, T. C., Chen, F., Zambrano, A., Abraha, A., Lagalwar, S., Guilfoyle, A. L., Lu, M., Fu, Y., Garcia-Sierra, F., LaPointe, N., Miller, R., Berry,
Extracellular Tau Is Influenced by Variability in Tau

48. Guo, J. L., and Lee, V. M. (2011) Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J. Biol. Chem. 286, 15317–15331

49. Nickel, W., and Rabouille, C. (2009) Mechanisms of regulated unconventional protein secretion. Nat. Rev. Mol. Cell Biol. 10, 148–155

50. Gómez-Ramos, A., Díaz-Hernández, M., Rubio, A., Mirás-Portugal, M. T., and Avila, J. (2008) Extracellular Tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells. Mol. Cell Neurosci. 37, 673–681

51. Gómez-Ramos, A., Díaz-Hernández, M., Rubio, A., Díaz-Hernández, J. I., Mirás-Portugal, M. T., and Avila, J. (2009) Characteristics and consequences of muscarinic receptor activation by Tau protein. Eur. Neuropsychopharmacol. 19, 708–717

52. Danzer, K. M., Haasen, D., Karow, A. R., Moussaud, S., Habeck, M., Giese, A., Kretzschmar, H., Hengerer, B., and Kostka, M. (2007) Different species of α-synuclein oligomers induce calcium influx and seeding. J. Neurosci. 27, 9220–9232

53. Demuro, A., Mina, E., Kayed, R., Milton, S. C., Parker, I., and Glabe, C. G. (2005) Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem. 280, 17294–17300

54. LaFerla, F. M. (2002) Calcium dyshomeostasis and intracellular signaling in Alzheimer disease. Nat. Rev. Neurosci. 3, 862–872

55. Mattson, M. P., and Chan, S. L. (2003) Neuronal and glial calcium signaling in Alzheimer disease. Cell Calcium 34, 385–397

56. Stutzmann, G. E. (2005) Calcium dysregulation, IP3 signaling, and Alzheimer disease. Neuroscientist 11, 110–115

57. Saman, S., Kim, W., Raya, M., Visnick, Y., Miro, S., Saman, S., Jackson, B., McKee, A. C., Alvarez, V. E., Lee, N. C., and Hall, G. F. (2012) Exosome-associated tau is seeded in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J. Biol. Chem. 287, 3842–3849

58. Simón, D., García-García, E., Gómez-Ramos, A., Falcón-Pérez, J. M., Díaz-Hernández, M., Fernández, F., and Avila, J. (2012) Tau overexpression results in its secretion via membrane vesicles. Neurodegener. Dis. 10, 73–75

59. Chang, H. C., Samaniego, F., Nair, B. C., Buonaguro, L., and Ensoli, B. (1997) HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 11, 1421–1431

60. Simón, D., García-García, E., Royo, F., Falcón-Pérez, J. M., and Avila, J. (2012) Proteostasis of Tau. Tau overexpression results in its secretion via membrane vesicles. FEBS Lett. 586, 47–54

61. Fauré, J., Lachenal, G., Court, M., Hirrlinger, J., Chatellard-Causse, C., Blot, B., Grange, J., Schoehn, G., Goldberg, Y., Boyer, V., Kirchhoff, F., Rajo, G., Garin, J., and Sadoul, R. (2006) Exosomes are released by cultured cortical neurons. Mol. Cell Neurosci. 31, 642–648

62. Santa-Maria, I., Varghese, M., Ksiezek-Reding, H., Dzhuin, A., Wang, J., and Pasinetti, G. M. (2012) Paired helical filaments from Alzheimer disease brain induce intracellular accumulation of Tau in aggresomes. J. Biol. Chem. 287, 20522–20533

63. Dayanandan, R., Van Slegtenhorst, M., Mack, T. G., Ko, L., Yen, S. H., Leroy, K., Brion, J. P., Anderton, B. H., Hutton, M., and Lovestone, S. (1999) Mutations in Tau reduce its microtubule binding properties in intact cells and affect its phosphorylation. FEBS Lett. 446, 228–232

64. Baker, M., Litvan, I., Houlden, H., Adamson, J., Dickson, D., Perez-Tur, J., Hardy, J., Lynch, T., Bigio, E., and Hutton, M. (1999) Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum. Mol. Genet. 8, 711–715

65. Houlden, H., Baker, M., Morris, H. R., MacDonald, N., Pickerling-Brown, S., Adamson, J., Lees, A. J., Rossor, M. N., Quinn, N. P., Kertesz, A., Khan, M. N., Hardy, J., Lantos, P. L., St George-Hyslop, P., Munoz, D. G., Mann, D., Lang, A. E., Bergeron, C., Bigio, E. H., Litvan, I., Bhata, K. P., Dickson, D., Wood, N. W., and Hutton, M. (2001) Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 56, 1702–1706

66. Myers, A. J., Kaleem, M., Marlowe, L., Pittman, A. M., Lees, A. J., Fung, H. C., Duckworth, J., Leung, D., Gibson, A., Morris, C. M., de Silva, R., and
Extracellular Tau Is Influenced by Variability in Tau

Hardy, J. (2005) The H1c haplotype at the MAPT locus is associated with Alzheimer disease. *Hum. Mol. Genet.* **14**, 2399–2404

Simón-Sánchez, J., Schulte, C., Bras, J. M., Sharma, M., Gibbs, J. R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S. W., Hernandez, D. G., Krüger, R., Federoff, M., Klein, C., Goate, A., Perlmuter, J., Bonin, M., Nalls, M. A., Illig, T., Gieger, C., Houlden, H., Steffens, M., Okun, M. S., Racette, B. A., Cookson, M. R., Foote, K. D., Fernandez, H. H., Traynor, B. J., Schreiber, S., Arepalli, S., Zonozi, R., Gwinn, K., van der Brug, M., Lopez, G., Chanock, S. J., Schatzkin, A., Park, Y., Hollenbeck, A., Gao, J., Huang, X., Wood, N. W., Lorenz, D., Deuschl, G., Chen, H., Riess, O., Hardy, J. A., Singleton, A. B., and Gasser, T. (2009) Genome-wide association study reveals genetic risk underlying Parkinson disease. *Nat. Genet.* **41**, 1308–1312

Myers, A. J., Pittman, A. M., Zhao, A. S., Rohrer, K., Kaleem, M., Marlowe, L., Lees, A., Leung, D., McKeith, I. G., Perry, R. H., Morris, C. M., Trojanowski, J. Q., Clark, C., Karlawish, J., Arnold, S., Forman, M. S., Van Deerlin, V., de Silva, R., and Hardy, J. (2007) The MAPT H1c risk haplotype is associated with increased expression of Tau and especially of 4 repeat containing transcripts. *Neurobiol. Dis.* **25**, 561–570